Omeros Corporation (OMER)

NASDAQ: OMER · IEX Real-Time Price · USD
2.61
-0.04 (-1.32%)
At close: Jun 24, 2022 4:00 PM
2.64
+0.03 (1.15%)
After-hours: Jun 24, 2022 7:18 PM EDT
-1.32%
Market Cap 174.55M
Revenue (ttm) -21.06M
Net Income (ttm) 196.31M
Shares Out 66.88M
EPS (ttm) 3.14
PE Ratio 0.83
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,817,268
Open 2.70
Previous Close 2.65
Day's Range 2.61 - 2.85
52-Week Range 1.86 - 16.57
Beta 0.84
Analysts Buy
Price Target 12.24 (+369.0%)
Earnings Date Aug 8, 2022

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for i... [Read more...]

Industry Pharmaceuticals
IPO Date Oct 8, 2009
CEO Gregory Demopulos
Employees 213
Stock Exchange NASDAQ
Ticker Symbol OMER
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for OMER stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 368.97% from the latest price.

Price Target
$12.24
(368.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Omeros Announces Webcast Details for Annual Meeting of Shareholders

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, Jun...

Omeros Corporation Reports First Quarter 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics f...

Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022, on Tuesday, May 10, 2022...

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab...

Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics f...

Why Earnings Season Could Be Great for Omeros (OMER)

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesd...

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)...

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency's Comp...

Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Grou...

OMER EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About...

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- WHY: New York, N.Y., December 19, 2021.

Do Options Traders Know Something About Omeros (OMER) Stock We Don't?

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and ...

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Om...

Omeros Offloads Cataract Med Omidria To Rayner Surgical In Deal Valued Over $1B

Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200 million in commercial milestones. Omidria (ph...

Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited. Expected to close on...

Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates

Omeros (OMER) delivered earnings and revenue surprises of 42.22% and 2.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Omeros: Q3 Earnings Insights

Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Omeros Corporation Reports Third Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years

Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.  Treatment with narsoplim...

Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with Ig...

Omeros' Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in kidne...

Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 192% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive t...

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, November ...

Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Beaten-Down Biotech Stocks -- Can They Recover?

Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.

Other symbols: AVIRNVAX